Sara J C Gosline
Overview
Explore the profile of Sara J C Gosline including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
729
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen B, Bottomly D, Kohnke T, Wang A, Lin H, Johnson K, et al.
Blood
. 2025 Feb;
PMID: 40009487
MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2...
2.
Joshi S, Huang A, Pittsenbarger J, Shinde U, Posso C, Piehowski P, et al.
Haematologica
. 2025 Feb;
PMID: 39945005
Not available.
3.
Zitnik M, Li M, Wells A, Glass K, Morselli Gysi D, Krishnan A, et al.
Bioinform Adv
. 2024 Aug;
4(1):vbae099.
PMID: 39143982
Summary: Network biology is an interdisciplinary field bridging computational and biological sciences that has proved pivotal in advancing the understanding of cellular functions and diseases across biological systems and scales....
4.
Nguyen H, Kohl E, Bade J, Eng S, Tosevska A, Al Shihabi A, et al.
Cell Rep Methods
. 2024 May;
4(5):100772.
PMID: 38744290
Localized cutaneous neurofibromas (cNFs) are benign tumors that arise in the dermis of patients affected by neurofibromatosis type 1 syndrome. cNFs are benign lesions: they do not undergo malignant transformation...
5.
Modak R, de Oliveira Rebola K, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2245-2259.
PMID: 38451486
Purpose: Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions, driving disease progression, and promoting drug resistance in acute myeloid...
6.
Feng S, Calinawan A, Pugliese P, Wang P, Ceccarelli M, Petralia F, et al.
Cell Rep Methods
. 2024 Feb;
4(2):100708.
PMID: 38412834
Tumor deconvolution enables the identification of diverse cell types that comprise solid tumors. To date, however, both the algorithms developed to deconvolve tumor samples, and the gold-standard datasets used to...
7.
Petralia F, Ma W, Yaron T, Caruso F, Tignor N, Wang J, et al.
Cell
. 2024 Feb;
187(5):1255-1277.e27.
PMID: 38359819
Despite the successes of immunotherapy in cancer treatment over recent decades, less than <10%-20% cancer cases have demonstrated durable responses from immune checkpoint blockade. To enhance the efficacy of immunotherapies,...
8.
Pino J, Posso C, Joshi S, Nestor M, Moon J, Hansen J, et al.
Cell Rep Med
. 2024 Jan;
5(1):101359.
PMID: 38232702
Acute myeloid leukemia is a poor-prognosis cancer commonly stratified by genetic aberrations, but these mutations are often heterogeneous and fail to consistently predict therapeutic response. Here, we combine transcriptomic, proteomic,...
9.
Joshi S, Piehowski P, Liu T, Gosline S, McDermott J, Druker B, et al.
Annu Rev Pharmacol Toxicol
. 2023 Sep;
64:455-479.
PMID: 37738504
Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often...
10.
Gosline S, Velickovic M, Pino J, Day L, Attah I, Swensen A, et al.
Mol Cell Proteomics
. 2023 Jun;
22(8):100592.
PMID: 37328065
The need for a clinically accessible method with the ability to match protein activity within heterogeneous tissues is currently unmet by existing technologies. Our proteomics sample preparation platform, named microPOTS...